Harini Krishnan
Stony Brook University
17 Papers
65 Citations
Harini Krishnan is an academic researcher from Stony Brook University. The author has contributed to research in topics: Podoplanin & PDPN. The author has an hindex of 11, co-authored 17 publications. Previous affiliations of Harini Krishnan include University of Medicine and Dentistry of New Jersey & Rowan University.
Chat about Author
Papers
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: The challenge ahead
William H. Goodson,Leroy Lowe,David O. Carpenter,Michael Gilbertson,Abdul Manaf Ali,Adela Lopez de Cerain Salsamendi,Ahmed Lasfar,Amancio Carnero,Amaya Azqueta,Amedeo Amedei,Amelia K Charles,Andrew Collins,Andrew Ward,Anna C. Salzberg,Annamaria Colacci,Ann-Karin Olsen,Arthur Berg,Barry J. Barclay,Binhua P. Zhou,Carmen Blanco-Aparicio,Carolyn J. Baglole,Chenfang Dong,Chiara Mondello,Chia-Wen Hsu,Christian C. Naus,Clement G. Yedjou,Colleen S. Curran,Dale W. Laird,Daniel C. Koch,Danielle J Carlin,Dean W. Felsher,Debasish Roy,Dustin G. Brown,Edward A. Ratovitski,Elizabeth P. Ryan,Emanuela Corsini,Emilio Rojas,Eun-Yi Moon,Ezio Laconi,Fabio Marongiu,Fahd Al-Mulla,Ferdinando Chiaradonna,Firouz Darroudi,Francis Martin,Frederik J. van Schooten,Gary S. Goldberg,Gerard Wagemaker,Gladys N. Nangami,Gloria M. Calaf,Gloria M. Calaf,Graeme Williams,Gregory T. Wolf,Gudrun Koppen,Gunnar Brunborg,H. Kim Lyerly,Harini Krishnan,Hasiah Ab Hamid,Hemad Yasaei,Hideko Sone,Hiroshi Kondoh,Hosni Salem,Hsue-Yin Hsu,Hyun Ho Park,Igor Koturbash,Isabelle R. Miousse,A. Ivana Scovassi,James E. Klaunig,Jan Vondráček,Jayadev Raju,Jesse Roman,Jesse Roman,John Pierce Wise,Jonathan Whitfield,Jordan Woodrick,Joseph Christopher,Josiah Ochieng,Juan Fernando Martinez-Leal,Judith Weisz,Julia Kravchenko,Jun Sun,Kalan R. Prudhomme,Kannan Badri Narayanan,Karine A. Cohen-Solal,Kim Moorwood,Laetitia Gonzalez,Laura Soucek,Le Jian,Leandro S. D'Abronzo,Liang Tzung Lin,Lin Li,Linda S M Gulliver,Lisa J. McCawley,Lorenzo Memeo,Louis Vermeulen,Luc Leyns,Luoping Zhang,Mahara Valverde,Mahin Khatami,Maria Romano,Marion Chapellier,Marc A. Williams,Mark Wade,Masoud H. Manjili,Matilde E. Lleonart,Menghang Xia,Michael J. Gonzalez,Michalis V. Karamouzis,Micheline Kirsch-Volders,Monica Vaccari,Nancy B. Kuemmerle,Nancy B. Kuemmerle,Neetu Singh,Nichola Cruickshanks,Nicole Kleinstreuer,Nik van Larebeke,Nuzhat Ahmed,Olugbemiga Ogunkua,Periyadan K. Krishnakumar,Pankaj Vadgama,Paola A. Marignani,Paramita M. Ghosh,Patricia Ostrosky-Wegman,Patricia A. Thompson,Paul Dent,Petr Heneberg,Philippa D. Darbre,Po Sing Leung,Pratima Nangia-Makker,Qiang Shawn Cheng,R. Brooks Robey,R. Brooks Robey,Rabeah Al-Temaimi,Rabindra Roy,Rafaela Andrade-Vieira,Ranjeet Kumar Sinha,Rekha Mehta,Renza Vento,Renza Vento,Riccardo Di Fiore,Richard Ponce-Cusi,Rita Dornetshuber-Fleiss,Rita Dornetshuber-Fleiss,Rita Nahta,Robert C. Castellino,Roberta Palorini,Roslida Abd Hamid,Sabine A. S. Langie,Sakina E. Eltom,Samira A. Brooks,Sandra Ryeom,Sandra S. Wise,Sarah N Bay,Shelley A. Harris,Shelley A. Harris,Silvana Papagerakis,Simona Romano,Sofia Pavanello,Staffan Eriksson,Stefano Forte,Stephanie C. Casey,Sudjit Luanpitpong,Tae-Jin Lee,Takemi Otsuki,Tao Chen,Thierry Massfelder,Thomas Sanderson,Tiziana Guarnieri,Tove Hultman,Valérian Dormoy,Valérian Dormoy,Valerie Odero-Marah,Venkata S. Sabbisetti,Véronique Maguer-Satta,W. Kimryn Rathmell,Wilhelm Engström,William K. Decker,William H. Bisson,Yon Rojanasakul,Yunus A. Luqmani,Zhenbang Chen,Zhiwei Hu +180 more
TL;DR: Low-dose exposures to common environmental chemicals that are deemed safe individually may be combining to instigate carcinogenesis, thereby contributing to the incidence of cancer.
Podoplanin: An emerging cancer biomarker and therapeutic target.
Harini Krishnan,Julie Rayes,Tomoyuki Miyashita,Genichiro Ishii,Edward P. Retzbach,Stephanie A. Sheehan,Ai Takemoto,Yao Wen Chang,Kazue Yoneda,Jun Asai,Lasse Jensen,Lushun Chalise,Atsushi Natsume,Gary S. Goldberg +13 more
TL;DR: This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.
Src activates Abl to augment Robo1 expression in order to promote tumor cell migration
P. Raaj Khusial,Bhaskar Vadla,Harini Krishnan,Trudy F. Ramlall,Yongquan Shen,Hitoshi Ichikawa,Jian Guo Geng,Gary S. Goldberg +7 more
TL;DR: It is reported here that Src activates Abl to stabilize Robo1 in order to promote cell migration and inhibition of Abl kinase activity by siRNA or kinase blockers decreased Robo1 protein levels and suppressed the migration of transformed cells.
Src and podoplanin forge a path to destruction.
TL;DR: This review discusses how Src and PDPN forge a path to tissue destruction, and how they can serve as targets for therapeutics to combat cancer and arthritis.
22
SRC points the way to biomarkers and chemotherapeutic targets.
TL;DR: The role of Src in cell migration and contact normalization is discussed, with emphasis on Cas and Abl pathways, which illuminates several chemotherapeutic targets and may lead to the identification of new biomarkers and the development of effective anticancer treatments.
21